Emcure Pharma Appoints Former Sun Pharma CFO C S Muralidharan as Independent Director
New Delhi: Emcure Pharmaceuticals Limited has announced the appointment of C. S. Muralidharan as an Additional Director (Non-Executive and Independent) and as an Independent Director of the company. The appointment will be effective from April 1, 2026, subject to approval of the company's shareholders.
The decision was approved by the Board of Directors at its meeting held on March 9, 2026, following the recommendation of the Nomination and Remuneration Committee. The board meeting commenced at 12:15 PM (IST) and concluded at 12:40 PM (IST).
According to the company’s regulatory filing made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Muralidharan will serve as an Independent Director for a first term of three consecutive years, beginning April 1, 2026.
Mr. C. S. Muralidharan has overall 40 years of corporate experience spread across hydro-carbon and pharmaceutical sectors. He has held various board and senior leadership positions across multiple entities in India, Asia and Europe. He has had proactive engagements with the Board demonstrating strong partnership on Strategy M&A transactions, enterprise risk management, capital restructuring, enterprise transformation and ESG initiatives. He has previously worked with organizations like Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group and in his last role, was associated with Sun Pharmaceutical Industries Limited, as Group Chief Financial Officer, where he was responsible for global finance, strategy, M&A, investor relations, governance and compliance.
Mr. Muralidharan is a Cost & Management Accountant with a Master’s degree in Commerce and has completed the Executive Program in General Management from Booth School of Business, University of Chicago.
The company further confirmed that Muralidharan is not debarred by any order of the Securities and Exchange Board of India (SEBI) and is not related to any of the directors or key managerial personnel of the company.
